Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Phanes Therapeutics
Humanetics Corporation
University of Pittsburgh
Case Comprehensive Cancer Center
Acrotech Biopharma Inc.
University of Texas Southwestern Medical Center
Holy Cross Hospital, Florida
Radiation Therapy Oncology Group
UNC Lineberger Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Alliance for Clinical Trials in Oncology
Amgen
M.D. Anderson Cancer Center
University of Alabama at Birmingham
University of Alabama at Birmingham
University of Chicago
Northwestern University